• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Cytogen reports on Quadramet status

Article

Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the company’s bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont

Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the company’s bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont Pharmaceuticals to expedite the changeover, according to the company. North Billerica, MA-based Du Pont will continue to manufacture Quadramet.

The two companies initiated an interim agreement June 2 in which they determined that Du Pont would identify marketing partner candidates for Cytogen (SCAN Special Report 6/98). The agreement has been extended through the end of this month, pending the final selection of a new partner and the completion of Cytogen’s marketing arrangements with Du Pont. Cytogen has taken over the identification and selection of candidates as the process continues.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.